Gyre Therapeutics, Inc.（NASDAQ:GYRE）总裁马松江近日报告，在两天内出售了4,000股普通股，总价值46,280美元。该生物科技公司目前市值为10.2亿美元。交易发生在2025年3月11日和3月12日，售价在每股11.4美元至11.74美元之间。这些交易是根据2024年9月制定的Rule ...

根据报道，生物制药公司Gyre Therapeutics, Inc.（NASDAQ:GYRE）总裁兼董事马松江近期出售了该公司4,000股普通股。该公司目前市值约9.57亿美元。根据 InvestingPro 分析，GYRE目前的交易价格高于其公允价值，整体财务健康状况评级为"良好"。这些交易是在3月3日和3月4日根据预先制定的Rule ...

2025年3月13日， Gyre Therapeutics（GYRE）披露2笔公司内部人交易情况。董事Ma Songjiang于2025年3月12日卖出2000股。 2025年3月13日 董事 Ma Songjiang 2025年3月11日 卖出 2000 11.40 2.28万 2025年3月13日 董事 Ma Songjiang 2025年3月12日 卖出 2000 11.74 2.35万 2 ...

Stock analysts at Noble Financial issued their FY2024 earnings per share (EPS) estimates for Gyre Therapeutics in a research report issued to clients and investors on Tuesday, March 11th. Noble ...

Noble Capital initiated coverage of Gyre Therapeutics (GYRE) with an Outperform rating. Gyre is developing drugs for inflammatory diseases that ...

3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Several large investors have recently bought and sold shares of GYRE. Geode Capital Management LLC ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated ...

Over the last 7 days, the United States market has experienced a 3.7% decline, although it has shown a 6.9% increase over the past year with earnings projected to grow by 14% annually. In this context ...

SAN DIEGO—Ma Songjiang, President of Gyre Therapeutics, Inc. (NASDAQ:GYRE), a $1.03 billion market cap biotech company, executed sales of common stock valued at a total of $46,360 over two ...